Rationale: The bone morphogenetic receptor type II gene is the major genetic determinant for the inherited form of pulmonary arterial hypertension. However, deleterious mutations of this gene are not observed in the majority of subjects who develop the condition spontaneously and familial disease displays age-and sex-dependent penetrance indicating the requirement for additional environmental and/or genetic modifiers for disease development. Methods: We investigated polymorphic variation of the serotonin transporter gene, a biological candidate for predisposition to this vascular disorder. Results: No significant evidence of association between alleles of the serotonin transporter gene and pulmonary hypertension was detected, nor did we observe a relationship with age of onset in familial and idiopathic disease.
Introduction:
Pulmonary arterial hypertension (PAH) is a severe disorder characterised by a sustained elevation of pulmonary arterial resistance consequent upon the vascular remodelling of small pulmonary arterioles. This process involves proliferation and hyperplasia of endothelial and smooth muscle cells with an increase in the extracellular matrix. The disease most frequently manifests in the 4 th decade of life and in the absence of treatment leads to right heart failure [1, 2] .
To aid clinical management, distinction has been made between familial (FPAH), idiopathic or sporadic disease (IPAH) and PAH associated with other diseases or exposure to exogenous agents for example, appetite suppressants containing fenfluramine derivatives (APAH) [3] .
The genetic basis of familial PAH has recently been clarified. Heterozygous mutations of Although comprehensive epidemiological studies are awaited, the penetrance of BMPR2 mutant alleles in families whilst reduced may be as high as 50% in some families [Machado et al., submitted] . These findings imply the existence of additional genetic and/or environmental factors, necessary for disease pathogenesis [11] . Recently, reports linking the mitogen serotonin 5-hydroxytryptamine transporter (5-HTT) with PAH have generated attention.
Internalisation of indoleamine by 5-HTT mediates the stimulatory effects of serotonin (5-HT) on cell proliferation [12] . Increased expression of the 5-HTT gene has been shown to drive growth responses of pulmonary artery smooth muscle cells (PASMCs) derived from patients following 5-HT exposure leading to speculation that the 5-HT pathway may act in antagonism to the predominantly growth inhibitory effects of BMP signalling ( Figure 1 ). To examine the genetic basis of the differential growth effects of 5-HT on PASMCs, Eddahibi et al.
investigated a functional 44 base pair insertion/deletion polymorphism (5-HTTLPR) in the promoter of the gene [13] . The insertion allele (I), corresponding to 16 units of a 20-23bp tandem repeat (VNTR), increases transcript expression by as much as three-fold over the 14 repeat unit deletion allele (D). The molecular basis of regulation of expression is as yet unclear [14] . The 5-HTTLPR insertion allele was found to be significantly over-represented (65%) amongst a cohort of 69 French IPAH subjects by comparison to the frequency observed in controls (27%) [13] . Taken together these data have been interpreted to support a role for variation of 5-HTT conferring susceptibility for PAH.
It has become widely accepted that assessment of association studies must be guarded due to the prevalence of false-positive results. Validation may come from replication studies that may confirm or reject association results [15] . Here, we have examined the role of variation of 5-HTT in PAH predisposition by investigating (I) a cohort of subjects comprising 259 IPAH cases and (II) 133 subjects each with either a family history of PAH and/or identified germline mutations. Further we added 136 subjects diagnosed with APAH representing a total disease study population of 528 subjects.
Materials and methods

Patients and Control populations
Ethical permission for these studies was provided by the local ethics committee or Institutional Review Board. All patients provided written informed consent. The diagnosis of pulmonary arterial hypertension was confirmed through clinical evaluation, chest radiography, electrocardiography, Doppler echocardiography, right heart catheterisation and/or histological analysis of the pulmonary vasculature derived from post-mortem. The FPAH and IPAH-mutation positive cohort comprised of 133 subjects, 82 of whom had a recorded family history of PAH while the remainder were diagnosed as idiopathic but had been shown to harbour a heterozygous germline mutation in the BMPR2 gene. For the purposes of analysis patients were classified as idiopathic when disease was sporadic and deleterious mutation was not detected following comprehensive screening of all coding regions and exon-intron boundaries as previously described [6, Aldred et al, submitted] . The APAH cohort (n=136) was composed of subjects with connective tissue disease (n=59), thromboembolic disease (n=42), congenital heart disease (n=15), portal hypertension (n=11) and HIV infection (n=9). Age of onset data was not available for the majority of this group.
Measurements of mean pulmonary arterial pressure (mPAP), cardiac output (CO) and pulmonary vascular resistance (PVR) were available for up to 86 FPAH/IPAH-mutation positive, 215 IPAH and 76 APAH cases. In 15 FPAH cases, the presence of disease was confirmed by histological analysis of post-mortem material. Patients were ascertained by specialist centres for the management of PAH from Germany (n=109), Poland (n=16), the USA (n=61) and the UK (n=316). All patients and controls (n=353) were of self-identified European ancestry.
Genotyping and statistical analysis
Genotyping of 5-HTTLPR was performed as described [13] . Briefly, the polymorphic site (deletion=484bp; insertion=528bp) was amplified using standard cycling conditions (annealing temperature, 61°C from data published previously [13] . Linkage disequilibrium (D') between the two polymorphisms from unphased genotype data was determined using HAPLOVIEW 3.2,
(http://www.broad.mit.edu/mpg/haploview/)
Results:
The haemodynamic features at the time of diagnosis were summarised for each PAH category (Table 1) . The FPAH/IPAH-mutation positive case group differed significantly to the idiopathic (mutation negative) and APAH cohorts likely reflecting more severe disease. (Table 2 ) together with the intron 2 VNTR in a subset of cases and controls ( were also subdivided by sex and variation of 5-HTTPLR compared to controls (data not shown). In both patient groups, gender-specific 5-HTTPLR genotype distributions were concordant with controls.
Discussion:
This study sought to examine the role of variation within the gene encoding the serotonin transporter in predisposition to and modification of the development of PAH. Pulmonary vascular lesions in PAH display markedly elevated levels of 5-HTT whilst explant-derived pulmonary vascular smooth muscle cells exhibit increased 5-HT uptake compared to non-PAH implicating the serotonin transporter as a contributor to vascular remodelling [13] . We sought to investigate association of genetic variation of the 5-HTT gene with familial, idiopathic and associated forms of the disorder by genotyping two common variable repeat sequences. The first is located within the promoter, 5-HTTLPR, and the other in intron 2 of the gene. In addition to the recently reported correlation of the 5-HTTLPR I/I genotype with IPAH, both polymorphisms have been previously shown to be associated with a number of behavioural disorders, including depression and schizophrenia susceptibility [13, 18, 19 ]. An epidemiological study testing the onset of depression in response to stress found diagnosable depression and suicidality was more common in individuals heterozygous or homozygous for the 5-HTTLPR deletion allele [18] . By contrast, a meta-analysis based on all published association studies between schizophrenia and variation in 5-HTT showed highly significant evidence for association with the STin2.12 allele of the intron 2 VNTR but none with 5-HTTPLR [19] . PAH is a rare disorder which shows monogenic inheritance in at least 6% of cases [1] . Hence, in seeking to identify disease susceptibility alleles and, in particular, to achieve replication of previous evidence for allelic association, extensive collaboration is necessary to attain sufficient subjects with PAH. In this report, we have investigated cohorts with sufficient power (>95% at a significance level of 0.05) to detect association for any allele conferring a relative risk comparable to that previously reported for 5-HTT in IPAH [13] . We have now
shown that allele and genotype frequencies do not differ between PAH cohorts and controls.
These findings indicate that neither the promoter VNTR polymorphism known to underlie variability in serotonin transporter expression [14] nor a tandem repeat within intron 2 of the gene are likely to contribute to disease development and risk to subjects with BMPR2 mutation or independently confer susceptibility to idiopathic or associated forms of disease.
We also questioned whether inherited variation at the 5-HTTPLR locus might in part explain the variable age of onset, a characteristic of PAH within and between kindreds. We observed no significant difference between the average age of onset in FPAH/IPAH-mutation positive and IPAH subjects when differentiated by 5-HTTPLR genotype. Nevertheless, it remains possible that 5-HTT variants may alter this clinical parameter in other subsets of PAH. To date, the most discriminant risk factor for disease development known is gender with females favoured at a ratio of 2:1. We found similar distribution of 5-HTTPLR alleles between males and females with PAH, in keeping with Hardy-Weinberg estimates. As LD between 5-HTTLPR and the intron 2 VNTR is low (D' 0.42), these analyses likely represent a survey of relatively independent regions of 5-HTT and, together, suggest that it is unlikely to play a significant role in disease onset.
The mechanisms explaining the complex features of disease manifestation for inherited forms of PAH remain unclear. Whilst both environmental and genetic features are likely to contribute, the proportion of variance explained by either factor is unknown. As a consequence careful attention to methodological detail is required as more studies are
proposed and undertaken to examine the role of genetic variation in uncommon but complex disorders such as PAH. Specifically, the potential for substantial bias in these studies due to hidden population stratification must be recognised together with assessment of population cohorts of sufficient size to provide more robust reliability in the evaluation of allelic frequency differences. Finally, initial reports of disease association will most satisfactorily be interpreted when accompanied by independent cohort replication.
In summary, reduced penetrance of BMPR2 disease-causing alleles together with variability in the age of onset suggest a role for genetic risk factors in the pathogenesis of PAH. Whilst a plausible candidate for susceptibility, the gene encoding the serotonin transporter appears unlikely to confer significant risk to disease development or modify age of onset. 
